Research programme: large molecule anticancer therapeutics - JW Pharmaceutical
Alternative Names: Project B4 - JW PharmaceuticalLatest Information Update: 09 Oct 2024
At a glance
- Originator JW Pharmaceutical
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 07 Oct 2024 Preclinical trials in Cancer in South Korea (Parenteral), prior to October 2024 (JW Pharmaceutical pipeline, October 2024)